

Optimizing biological activity of Lactoferricin derived peptides: Conjugation with non peptidic motifs as a strategy

Daniel Castellar¹, Javier García¹, Zuly Rivera², Ricardo Fierro²

¹ Pharmacy Department, Universidad Nacional de Colombia– Bogotá D.C, Colombia

² Chemistry Department, Universidad Nacional de Colombia– Bogotá D.C, Colombia

<https://doi.org/10.17952/37EPS.2024.P2213>





INTRODUCTION


Synthetic peptides derived from Bovine Lactoferricin have been established as promising molecules against multiple cancers. The palindromic sequence **RWQWRWQWR** has demonstrated selective cytotoxic activity against breast and cervical cancers, establishing this peptide as a potential anticancer agent. To broaden the biological applications of this sequence, we utilized three different functional moieties to enhance the peptide's biological activities: i) **non-steroidal anti-inflammatory Drugs (NSAID)**, which could optimize the anticancer activity of the sequence by modulating anti-inflammatory signals; ii) **fluorescent probes**, enabling the peptide to be used as a bioanalytical tool in cancer cell imaging; and iii) **ferrocene**, which could enhance redox reactions within cancer cells. Some of these motifs proved useful for optimizing the cytotoxic activity of the core sequence and for enabling the peptide to be used in other applications such as cancer cell imaging.

METHODS


1). Solid Phase Peptide Synthesis




2). Peptide purification and Characterization



3). Cytotoxic Activity in Cancer Cells




4). Other biological assays



RESULTS AND DISCUSSION

NSAID– LfcinB conjugates



Code	Sequence	t _r (min)	Purity (%)	Expected mass (amu)	Experimental mass (amu)
(Orn) ₃ -(LfcinB) _{Pal}	OOORWQWRWQWR	5,7	99,9	1828,0000	1828,0125
NAP (Orn) ₃ -(LfcinB) _{Pal}	NAP-OOORWQWRWQWR	7,0	94,3	2040,0900	2040,1200
IBU (Orn) ₃ -(LfcinB) _{Pal}	IBU-OOORWQWRWQWR	7,5	97,7	2016,1200	2016,1340

Table 1. Characterization of NSAID conjugated peptides optimized with a polar Ornithine moiety spacer




Figure 1. Cytotoxic activity of the Ibuprofen conjugated peptide IBU (Orn)₃-(LfcinB)_{Pal} compared to the activity of the palindromic sequence and its non conjugated ornithine derivate against **A**) MCF-7 (breast cancer) and **B**) HeLa (cervical cancer) cells. Experiments were conducted in triplicates (n=3)

Code	Sequence	IC ₅₀ µM (HeLa)	IC ₅₀ µM (MFC-7)	IC ₅₀ µM Fibroblast (L929)	Hemolysis Selectivity (%) *	Index
(Orn) ₃ -(LfcinB) _{Pal}	OOORWQWRWQWR	>109	> 109	>109	< 10 %	N.A
NAP (Orn) ₃ -(LfcinB) _{Pal}	NAP-OOORWQWRWQWR	85	> 98	> 98	<10 %	>1
IBU (Orn) ₃ -(LfcinB) _{Pal}	IBU-OOORWQWRWQWR	29	55	> 81	<10 %	>2

Table 2. Summary of the cytotoxic activity of the NSAID conjugated peptides against cancer cells, fibroblast and erythrocytes. *Percentage of hemolysis is reported at a maximum concentration of 200 µg/mL

Ferrocene– Lfcin B conjugates





Figure 4. Representative RP-HPLC-chromatogram depicting the degradation process of the Ferrocene conjugated peptide optimized with an Ornithine moiety. **A**) Crude peptide **B**) Peptide after RP-SPE purification process

Fluorescent probes– Lfcin B conjugates



Code	Sequence	t _r (min)	Purity (%)	Expected mass (amu)	Experimental mass (amu)
(5(6) FAM)-(LfcinB) _{Pal}	(5(6) FAM)-RWQWRWQWR	8,2	96,9	1843,8100	1843,8088
(RhodB)-(LfcinB) _{Pal}	(RhodB)-RWQWRWQWR	*9,8 and 10,1	30,2 and 65,0	1910,9900	1910,9800

Table 3. Characterization of the fluorescent peptides obtained. * Rhodamine B peptide is a mixture of two isomers




Figure 2. Representative RP-HPLC-chromatogram of the Rhodamine B conjugated peptide presenting the pair of isomers detected by LC-ESI-QTOF (isotopic distribution showed) which correspond to an open ring–lactam equilibrium




Figure 3. Cytotoxic activity of the fluorescein and Rhodamine B conjugated peptides against MCF-7. Experiments were conducted in triplicates (n=3)




Figure 4. Fluorescence Microscopy images of MCF-7 cells incubated with 200 µg/mL of the RhodB conjugated peptide

CONCLUSION

The fluorescent probe Rhodamine B was successfully conjugated to the amino terminal region of the palindromic peptide, and the resulting fluorescent product retained the cytotoxic activity of the core sequence. Fluorescence microscopy revealed colocalization of the fluorescent peptide with MCF-7 cells, demonstrating its potential for cancer cell imaging.

Moreover, the conjugation of NSAID to the palindromic sequence was effectively achieved using an ornithine moiety, which enhanced the solubility profile. The ibuprofen-conjugated peptide exhibited enhanced selective cytotoxic activity against MCF-7 and HeLa cells, in contrast to the non-conjugated ornithine counterpart, which lost its cytotoxic activity.

For the case of the organometallic–LfcinB conjugates, a degradation process was observed in solution for the ferrocene-conjugated peptide with the same ornithine spacer, preventing this molecule from being evaluated in biological assays. Further experiments are required to study the stability of this organometallic conjugate.

Overall we successfully obtained novel Ibuprofen-LfcinB conjugates with enhanced selective cytotoxic activity against cervical and breast cancer cells. Additionally, we demonstrated the effect of conjugating the fluorescent probe Rhodamine B on the cytotoxic activity of the palindromic peptide and its utility for future experiments involving cell distribution and imaging.

ACKNOWLEDGEMENTS

We thank PhD students Karla Rodriguez, Natalia Ardila and PhD Andrea Barragan for their support with cytotoxic activity assays. We also thank Fernando Chavez and Dennis Salazar for their support with peptide synthesis and the research group leaders for their assessment.

REFERENCES

- Ardila-Chantré, N., Hernández-Cardona, A. K., Pineda-Castañeda, H. M., Estupiñán-Torres, S. M., Leal-Castro, A. L., Fierro-Medina, R., ... & García-Castañeda, J. E. (2020). RSC advances, 10(49), 29580-29586.
- Barragán Cárdenas, A., Insuasty Cepeda, D. S., Niño Ramírez, V. A., Umaña Pérez, A., Ochoa Zarzosa, A., López Meza, J. E., ... & García Castañeda, J. E. (2020). ChemistrySelect, 5(31), 9691-9700.